{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:07Z","timestamp":1787026807993,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071255"],"award-info":[{"award-number":["82071255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. Neurofilament light protein (NfL) is correlated with clinical severity of HD but relative data are the lack in the Chinese population. Reactive astrocytes are related to HD pathology, which predicts their potential to be a biomarker in HD progression. Our aim was to discuss the role of blood glial fibrillary acidic protein (GFAP) to evaluate clinical severity in patients with HD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Fifty-seven HD mutation carriers (15 premanifest HD, preHD, and 42 manifest HD) and 26 healthy controls were recruited. Demographic data and clinical severity assessed with the internationally Unified Huntington's Disease Rating Scale (UHDRS) were retrospectively analyzed. Plasma NfL and GFAP were quantified with an ultra-sensitive single-molecule (Simoa, Norcross, GA, USA) technology. We explored their consistency and their correlation with clinical severity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Compared with healthy controls, plasma NfL (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.0001) and GFAP (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) were increased in Chinese HD mutation carriers, and they were linearly correlated with each other (\n                    <jats:italic>r<\/jats:italic>\n                    = 0.612,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). They were also significantly correlated with disease burden, Total Motor Score (TMS) and Total Functional Capacity (TFC). The scores of Stroop word reading, symbol digit modalities tests, and short version of the Problem Behaviors Assessments (PBAs) for HD were correlated with plasma NfL but not GFAP. Compared with healthy controls, plasma NfL has been increased since stage 1 but plasma GFAP began to increase statistically in stage 2.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Plasma GFAP was correlated with plasma NfL, disease burden, TMS, and TFC in HD mutation carriers. Plasma GFAP may have potential to be a sensitive biomarker for evaluating HD progression.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2021.779890","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:12:48Z","timestamp":1637280768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Huajing","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingbang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-marc","family":"Burgunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Tabrizi, Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J Clin Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci Transl Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12035-008-8033-0","article-title":"Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration","volume":"38","author":"Perrot","year":"2008","journal-title":"Mol Neurobiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0172762","DOI":"10.1371\/journal.pone.0172762","article-title":"Tau or neurofilament light\u2014Which is the more suitable biomarker for Huntington's disease?","volume":"12","author":"Niemel\u00e4","year":"2017","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cne.24040","article-title":"The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting","volume":"524","author":"Von Bartheld","year":"2016","journal-title":"J Comp Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in huntington's disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front Mol Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"14489","DOI":"10.1523\/JNEUROSCI.1256-12.2012","article-title":"Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors","volume":"32","author":"Hamby","year":"2012","journal-title":"J Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jcbfm.2014.110","article-title":"Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions","volume":"34","author":"Boussicault","year":"2014","journal-title":"J Cereb Blood Flow Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3389\/fneur.2020.01054","article-title":"Comparing glial fibrillary acidic protein (gfap) in serum and plasma following mild traumatic brain injury in older adults","volume":"11","author":"Huebschmann","year":"2020","journal-title":"Front Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at risk for Huntington disease","author":"Zhang","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fncel.2015.00278","article-title":"Elusive roles for reactive astrocytes in neurodegenerative diseases","volume":"9","author":"Ben Haim","year":"2015","journal-title":"Front Cell Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.nbd.2020.104963","article-title":"The contribution of glial cells to Huntington's disease pathogenesis","volume":"143","author":"Wilton","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tins.2017.05.002","article-title":"Unravelling and exploiting astrocyte dysfunction in huntington's disease","volume":"40","author":"Khakh","year":"2017","journal-title":"Trends Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.drudis.2018.01.011","article-title":"Astrocytes as targets for drug discovery","volume":"23","author":"Gorshkov","year":"2018","journal-title":"Drug Discov Today."},{"key":"B23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/stem.3103","article-title":"Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice","volume":"38","author":"Wu","year":"2020","journal-title":"Stem Cells."},{"key":"B24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ejhg.2013.275","article-title":"WHODAS 2","volume":"22","author":"Downing","year":"2014","journal-title":"Eur J Hum Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","article-title":"CAG repeat number governs the development rate of pathology in Huntington's disease","volume":"41","author":"Penney","year":"1997","journal-title":"Ann Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1212\/NXI.0000000000000287","article-title":"Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease","volume":"3","author":"Vinther-Jensen","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.41.7.1117","article-title":"Morphometric analysis of the prefrontal cortex in Huntington's disease","volume":"41","author":"Sotrel","year":"1991","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1176\/jnp.14.1.37","article-title":"Behavior in Huntington's disease: dissociating cognition-based and mood-based changes","volume":"14","author":"Thompson","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2016.02.008","article-title":"Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease","volume":"25","author":"Martinez-Horta","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jnc.14574","article-title":"The S100B story: from biomarker to active factor in neural injury","volume":"148","author":"Michetti","year":"2019","journal-title":"J Neurochem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","article-title":"YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias","volume":"12","author":"Llorens","year":"2017","journal-title":"Mol Neurodegener."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.779890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:12:51Z","timestamp":1637280771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.779890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":31,"alternative-id":["10.3389\/fneur.2021.779890"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.779890","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"article-number":"779890"}}